Therapeutic Interleukin-6 Trans-signaling Inhibition by Olamkicept (sgp130Fc) in Patients With Active Inflammatory Bowel Disease

2021245 citationsJournal Articlehybrid Open Access

Authors

Stefan Schreiber · Hochschule für Angewandte Wissenschaften Kiel

Konrad Aden · Hochschule für Angewandte Wissenschaften Kiel

Joana P. Bernardes · Christian-Albrechts-Universität zu Kiel

Claudio Conrad

Florian Tran · Hochschule für Angewandte Wissenschaften Kiel

Hanna Höper

Valery Volk · Medizinische Hochschule Hannover

Neha Mishra

Abstract

Our data suggest that blockade of IL6 trans-signaling holds great promise for the therapy of IBD and should undergo full clinical development as a new immunoregulatory therapy for IBD. (EudraCT no., Nu 2016-000205-36).

Topics & Keywords

Inflammatory Bowel Disease Cytokine Signaling Pathways and Interactions IL-33, ST2, and ILC Pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Gastroenterology

Volume 160, Issue 7, pp. 2354-2366.e11

DOI: 10.1053/j.gastro.2021.02.062

Field-Weighted Citation Impact: 32.38